Cyto4B2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: Cyto4B2
• 英文别名: N-[2-(4-chlorophenyl)ethyl]thieno[2,3-d]pyrimidin-4-amine
• 化学式: C₁₄H₁₂ClN₃S
• 分子量: 289.788
• InChiKey: HBWGSCWAYXGITP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氯噻吩[2,3-D]嘧啶 在 ammonium hydroxide 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 Cyto4B2
  参考文献：
  名称：

  Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors

  摘要：

  Wnt 通路在发育和组织稳态中起着关键作用，由于它在许多癌症中的异常激活，抗癌药物的开发日益受到关注。在这项研究中，我们发现了一种新型小分子系列，其噻吩嘧啶支架可作为依赖β-catenin的Wnt通路的下游抑制剂。我们利用依赖 Wnt 的三阴性乳腺癌（TNBC）细胞系对这种新型化学类型进行了研究。通过结构活性关系（SAR）探索，发现了 5a、5d、5e 等低微摩尔化合物以及 9d 等具有喹唑啉支架的新型系列化合物。进一步的研究表明，这些化合物具有抑制 HCC1395 和 MDA-MB-468 TNBC 细胞系癌症存活的活性，而不会影响非癌症乳腺上皮细胞系 MCF10a。这种抗增殖作用与多西他赛治疗具有协同作用。总之，我们发现了可作为依赖于β-catenin的Wnt通路下游抑制剂的新型化学类型，它们可以扩大治疗TNBC的选择范围。

  DOI：

  10.3389/fphar.2022.1045102

文献信息

• AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
  申请人：Borchardt Allen J.

  公开号：US20100063047A1

  公开（公告）日：2010-03-11

  The present invention relates to compounds and methods which may be useful as inhibitors of H 1 R and/or H 4 R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

  本发明涉及化合物和方法，可能作为H1R和/或H4R的抑制剂用于治疗或预防炎症性、自身免疫性、过敏性和眼部疾病。
• 4-(3-BUTYNYL)AMINOPYRIMIDINE DERIVATIVES AS PEST CONTROL AGENTS FOR AGRICULTURAL AND HORTICULTURAL USE
  申请人：SDS Biotech K. K.

  公开号：EP2455371A1

  公开（公告）日：2012-05-23

  Novel 4-(3-butynyl)aminopyrimidine derivatives represented by general formula [I] are useful as pest control agents. In general formula [I], R1 is a mono- or bi-cyclic ring which may contain 0 to 3 heteroatoms, for example, phenyl or oxazolyl; R2 is a hydrogen atom, -R, -OR, -C(O)OR, -C(O)NHR, -CONR2 (wherein R is straight-chain or branched C1-8 alkyl, or the like), hydroxyalkyl, or the like; R3 is a hydrogen atom, a halogen atom, acyloxy represented by (straight-chain or branched C1-8 aliphatic hydrocarbon group) -CO-O-, or the like; and R4 is a hydrogen atom, a halogen atom, C1-6 alkyl, or the like, or alternatively, R4 and R3 together with the carbon atoms on the pyrimidine ring may form a thiophene ring, a pyrrole ring, an imidazole ring, a benzene ring, a pyrimidine ring, a furan ring, a pyrazine ring, or a pyrrolidine ring.

  通式[I]代表的新型 4-(3-丁炔基)氨基嘧啶衍生物可用作害虫防治剂。通式[I]中，R1 是单环或双环，可含有 0 至 3 个杂原子，例如苯基或噁唑基；R2 是氢原子、-R、-OR、-C(O)OR、-C(O)NHR、-CONR2（其中 R 是直链或支链 C1-8 烷基或类似物）、羟基烷基或类似物；R3 是氢原子、卤素原子、由（直链或支链 C1-8 脂肪族烃基）-CO-O- 代表的酰氧基或类似物；R4 是氢原子、卤素原子、C1-6 烷基或类似物，或者，R4 和 R3 与嘧啶环上的碳原子一起可形成噻吩环、吡咯环、咪唑环、苯环、嘧啶环、呋喃环、吡嗪环或吡咯烷环。
• Cytotoxic effects of NSL-1406, a new thienopyrimidine derivative, on leukocytes and osteoclasts
  作者：Jun Katada、Kiyoko Iijima、Michiko Muramatsu、Masamichi Takami、Emiko Yasuda、Miki Hayashi、Mari Hattori、Yoshio Hayashi

  DOI：10.1016/s0960-894x(99)00088-8

  日期：1999.3

  We synthesized a series of thienopyrimidine derivatives and examined their cytotoxic effects on several eel lines. One of the derivatives, NSL-1406, was shown to exert potent cytotoxic effects on leukemia cell line including P388 cells and J774 cells. It was also inhibitory on mouse osteoclasts and suppressed the in vitro bone resorption by osteoclasts at nanomolar concentrations. (C) 1999 Elsevier Science Ltd. All rights reserved.
• Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
  作者：Cédric Boudou、Luce Mattio、Alexey Koval、Valentin Soulard、Vladimir L. Katanaev

  DOI：10.3389/fphar.2022.1045102

  日期：——

  The Wnt-pathway has a critical role in development and tissue homeostasis and has attracted increased attention to develop anticancer drugs due to its aberrant activation in many cancers. In this study, we identified a novel small molecule series with a thienopyrimidine scaffold acting as a downstream inhibitor of the β-catenin-dependent Wnt-pathway. This novel chemotype was investigated using Wnt-dependent triple-negative breast cancer (TNBC) cell lines. Structure activity relationship (SAR) exploration led to identification of low micromolar compounds such as 5a, 5d, 5e and a novel series with quinazoline scaffold such as 9d. Further investigation showed translation of activity to inhibit cancer survival of HCC1395 and MDA-MB-468 TNBC cell lines without affecting a non-cancerous breast epithelial cell line MCF10a. This anti-proliferative effect was synergistic to docetaxel treatment. Collectively, we identified novel chemotypes acting as a downstream inhibitor of β-catenin-dependent Wnt-pathway that could expand therapeutic options to manage TNBC.

  Wnt 通路在发育和组织稳态中起着关键作用，由于它在许多癌症中的异常激活，抗癌药物的开发日益受到关注。在这项研究中，我们发现了一种新型小分子系列，其噻吩嘧啶支架可作为依赖β-catenin的Wnt通路的下游抑制剂。我们利用依赖 Wnt 的三阴性乳腺癌（TNBC）细胞系对这种新型化学类型进行了研究。通过结构活性关系（SAR）探索，发现了 5a、5d、5e 等低微摩尔化合物以及 9d 等具有喹唑啉支架的新型系列化合物。进一步的研究表明，这些化合物具有抑制 HCC1395 和 MDA-MB-468 TNBC 细胞系癌症存活的活性，而不会影响非癌症乳腺上皮细胞系 MCF10a。这种抗增殖作用与多西他赛治疗具有协同作用。总之，我们发现了可作为依赖于β-catenin的Wnt通路下游抑制剂的新型化学类型，它们可以扩大治疗TNBC的选择范围。